Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy
Articolo
Data di Pubblicazione:
2007
Citazione:
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy / A. Aiuti, B. Cassani, G. Andolfi, M. Mirolo, L. Biasco, A. Recchia, F. Urbinati, C. Valacca, S. Scaramuzza, M. Aker, S. Slavin, M. Cazzola, D. Sartori, A. Ambrosi, C. Di Serio, M. Roncarolo, F. Mavilio, C. Bordignon. - In: THE JOURNAL OF CLINICAL INVESTIGATION. - ISSN 0021-9738. - 117:8(2007 Aug), pp. 2233-2240. [10.1172/JCI31666]
Abstract:
Gene transfer into HSCs is an effective treatment for SCID, although potentially limited by the risk of insertional mutagenesis. We performed a genome-wide analysis of retroviral vector integrations in genetically corrected HSCs and their multilineage progeny before and up to 47 months after transplantation into 5 patients with adenosine deaminase-deficient SCID. Gene-dense regions, promoters, and transcriptionally active genes were preferred retroviral integrations sites (RISs) both in preinfusion transduced CD34 + cells and in vivo after gene therapy. The occurrence of insertion sites proximal to protooncogenes or genes controlling cell growth and self renewal, including LMO2, was not associated with clonal selection or expansion in vivo. Clonal analysis of long-term repopulating cell progeny in vivo revealed highly polyclonal T cell populations and shared RISs among multiple lineages, demonstrating the engraftment of multipotent HSCs. These data have important implications for the biology of retroviral vectors, the dynamics of genetically modified HSCs, and the safety of gene therapy.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
A. Aiuti, B. Cassani, G. Andolfi, M. Mirolo, L. Biasco, A. Recchia, F. Urbinati, C. Valacca, S. Scaramuzza, M. Aker, S. Slavin, M. Cazzola, D. Sartori, A. Ambrosi, C. Di Serio, M. Roncarolo, F. Mavilio, C. Bordignon
Link alla scheda completa:
Link al Full Text: